UK markets closed

Newron Pharmaceuticals S.p.A. (NWPHF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
12.00+0.60 (+5.26%)
As of 09:30AM EDT. Market open.

Newron Pharmaceuticals S.p.A.

Via Antonio Meucci 3
Bresso, MI 20091
Italy
39 02 610 3461
https://www.newron.com

Sector(s)
Industry
Full-time employees22

Key executives

NameTitlePayExercisedYear born
Mr. Stefan WeberCEO & Executive Director515.59kN/A1965
Mr. Roberto GalliChief Financial OfficerN/AN/AN/A
Mr. Filippo MoriggiaVice President of OperationsN/AN/AN/A
Dr. Ravi Anand M.D., Ph.D.Chief Medical Officer1.19MN/A1957
Ms. Laura FaravelliVice President of Business DevelopmentN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company's product pipeline includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. In addition, it has a strategic partnership with Zambon for the commercialization of safinamide; and license agreement with Meiji Seika Pharma Co., Ltd., for research, develop, manufacture, and marketing of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.

Corporate governance

Newron Pharmaceuticals S.p.A.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.